{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Post-conditioning&page=23", "query": { "intervention": "Post-conditioning", "page": 23 }, "page_size": 10 }, "pagination": { "page": 23, "page_size": 10, "total_count": 690, "total_pages": 69, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Post-conditioning&page=24&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Post-conditioning&page=22&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-27T05:12:22.533Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01379209", "title": "Intravenous Administration of RGI-2001 in Patient Undergoing Allogenic Hematopoietic Stem Cell Transplantation (AHSCT)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Graft Versus Host Disease" ], "interventions": [ { "name": "RGI-2001", "type": "DRUG" }, { "name": "Calcineurin Inhibitors", "type": "DRUG" }, { "name": "Allogeneic Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Conditioning Regimen", "type": "DRUG" }, { "name": "Allogeneic Bone Marrow Transplantation", "type": "PROCEDURE" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Mofetil Mycophenolate", "type": "DRUG" }, { "name": "sirolimus", "type": "DRUG" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Regimmune Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2011-09", "completion_date": "2017-04", "has_results": false, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 6, "location_summary": "San Diego, California • Stanford, California • Tampa, Florida + 3 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Columbus", "state": "Ohio" }, { "city": "San Antonio", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01379209" }, { "nct_id": "NCT06991114", "title": "AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Refractory Rheumatoid Arthritis (RA)", "Idiopathic Inflammatory Myopathies (IIMs)", "Systemic Sclerosis (SSc)", "Rheumatoid Arthritis (RA", "IIM", "Myositis", "Scleroderma", "Sjogren Syndrome", "Sjogrens Disease" ], "interventions": [ { "name": "Allogeneic NK Cells", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Artiva Biotherapeutics, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 90, "start_date": "2025-07-09", "completion_date": "2029-01", "has_results": false, "last_update_posted_date": "2026-07-31", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 31, "location_summary": "Tuscaloosa, Alabama • Phoenix, Arizona • Tucson, Arizona + 27 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Chula Vista", "state": "California" }, { "city": "Covina", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06991114" }, { "nct_id": "NCT01413100", "title": "Scleroderma Treatment With Autologous Transplant (STAT) Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Systemic Scleroderma" ], "interventions": [ { "name": "Anti-Thymocyte Globulin", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" }, { "name": "Peripheral Blood Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Plerixafor", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG", "OTHER" ], "sponsor": "Fred Hutchinson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "70 Years", "sex": "ALL", "summary": "Up to 70 Years" }, "enrollment_count": 21, "start_date": "2011-09-15", "completion_date": "2024-09-11", "has_results": true, "last_update_posted_date": "2025-01-07", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 12, "location_summary": "Duarte, California • Los Angeles, California • Denver, Colorado + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Denver", "state": "Colorado" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01413100" }, { "nct_id": "NCT02234037", "title": "Physical Conditioning and Decitabine for Newly Diagnosed AML Patients Age ≥ 60", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Decitabine", "type": "DRUG" }, { "name": "Exercise", "type": "BEHAVIORAL" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "60 Years", "maximum_age": null, "sex": "ALL", "summary": "60 Years and older" }, "enrollment_count": 3, "start_date": "2013-11", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2017-01-30", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 1, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT02234037" }, { "nct_id": "NCT00034528", "title": "Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hemoglobinopathies", "Anemia, Sickle Cell", "Hemoglobin SC Disease", "Thalassemia", "Thalassemia Major" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "FK506", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2001-09", "completion_date": "2003-11", "has_results": false, "last_update_posted_date": "2013-05-01", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT00034528" }, { "nct_id": "NCT03367546", "title": "Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Sickle Cell Disease", "Thalassemia", "High Risk Hematologic Disorders", "Cerebral Adrenoleukodystrophy", "Inherited Metabolic Disorders" ], "interventions": [ { "name": "Blood and Marrow Transplant", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "0 Years", "maximum_age": "25 Years", "sex": "ALL", "summary": "0 Years to 25 Years" }, "enrollment_count": 5, "start_date": "2018-07-02", "completion_date": "2022-12-19", "has_results": false, "last_update_posted_date": "2024-07-12", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT03367546" }, { "nct_id": "NCT03030261", "title": "Elotuzumab, Pomalidomide, & Dexamethasone (Elo-Pom-Dex) With Second Autologous Stem Cell Transplantation for Relapsed Multiple Myeloma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Multiple Myeloma in Relapse" ], "interventions": [ { "name": "Elotuzumab", "type": "DRUG" }, { "name": "Pomalidomide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 25, "start_date": "2017-11-22", "completion_date": "2027-09-26", "has_results": true, "last_update_posted_date": "2026-01-12", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 2, "location_summary": "Denver, Colorado • St Louis, Missouri", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03030261" }, { "nct_id": "NCT05011422", "title": "Haploidentical Hematopoietic Stem Cell Transplantation With Ex Vivo TCR Alpha/Beta and CD19 Depletion in Pediatric Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Pediatric Hematologic Malignancies" ], "interventions": [ { "name": "Ex Vivo T-cell receptor alpha-beta and CD19+ Depletion using CliniMACs Plus", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "Washington University School of Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "30 Years", "sex": "ALL", "summary": "Up to 30 Years" }, "enrollment_count": 50, "start_date": "2022-11-03", "completion_date": "2029-05-31", "has_results": false, "last_update_posted_date": "2026-08-19", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 1, "location_summary": "St Louis, Missouri", "locations": [ { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT05011422" }, { "nct_id": "NCT03577431", "title": "Liver Transplantation With Tregs at MGH", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Liver Transplant" ], "interventions": [ { "name": "arTreg-CSB", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "mesna", "type": "DRUG" }, { "name": "everolimus", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 9, "start_date": "2019-03-29", "completion_date": "2026-02-05", "has_results": false, "last_update_posted_date": "2026-09-16", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT03577431" }, { "nct_id": "NCT06517641", "title": "Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Severe Aplastic Anemia" ], "interventions": [ { "name": "Haploidentical donor bone marrow transplant", "type": "DRUG" }, { "name": "Unrelated donor bone marrow transplant", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "3 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "3 Years to 75 Years" }, "enrollment_count": 60, "start_date": "2025-05-12", "completion_date": "2029-02-01", "has_results": false, "last_update_posted_date": "2026-02-17", "last_synced_at": "2026-10-27T05:12:22.533Z", "location_count": 25, "location_summary": "Birmingham, Alabama • Duarte, California • Los Angeles, California + 20 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06517641" } ] }